News

Leqembi®âˆ‡ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...
TMCnet13h
Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...
The Berkeley Scanner on MSN16h
Berkeley may ban plants close to buildings in top wildfire zones
Officials are set to consider a BFD proposal prohibiting plants within 5 feet of structures, called Zone 0, in the most ...
Gallaudet University21h
Biology students win big in NASA student research poster contest
Three Gallaudet Biology students won honors and cash prizes in this year's NASA DC Space Grant Consortium’s student poster ...
Norfolk Daily News21h
Wayne State biology students win first place in poster competition
Wayne State College biology students Anna DeGroot of Iowa and Laura Bettenhausen of Monroe won first place in the student ...
Biogen Inc.: Leqembi? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...